Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV)

18 filings reported holding ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") as of Q4 2022.
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 14,965,637 shares of 31,306,673 outstanding shares and own 47.8% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (4,810,508 shares), PERCEPTIVE ADVISORS LLC (3,007,858 shares), Sands Capital Ventures, LLC (1,652,605 shares), CITADEL ADVISORS LLC (1,634,104 shares), MARSHALL WACE, LLP (1,223,252 shares), WELLINGTON MANAGEMENT GROUP LLP (900,149 shares), FEDERATED HERMES, INC. (823,300 shares), NEA Management Company, LLC (481,677 shares), HealthCor Management, L.P. (284,201 shares), and BANK OF MONTREAL /CAN/ (42,444 shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.